
Genentech drug Gazyva (obinutuzumab) was approved
On Nov. 13, 2013, Genentech announced that it’s drug Gazyva (obinutuzumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with previously untreated CLL.
Gazyva is a monoclonal antibody designed to attach CD20, a protein found only on B-cells. It attacks targeted cells both directly and together with the body’s immune system.
Gazyva is the fifth cancer medicine from Genentech approved by the FDA in the past three years. Gayzva is the first medicine approved with the FDA’s Breakthrough Therapy Designation
Tags:
Source: Genentech
Credit:
